Kerala State Drugs Control dept. seeks curbs on inter-State drug procurement to ensure traceability

The Kerala State Drugs Control Department issued a formal request to the state cabinet seeking a temporary ban on the purchase of pharmaceutical products from suppliers outside the state. The department argues that the current practice makes it difficult to track the origin of medicines, raising the risk of counterfeit or substandard drugs entering the supply chain. Recent incidents involving spurious medicines in the state have heightened public concern, prompting officials to prioritize a system where every batch can be traced back to a verified source.

Under the proposed six‑month restriction, all pharmaceutical firms operating in Kerala would be required to source their inventory exclusively from authorised medical depots that are registered with the state drug authority. These depots must maintain detailed records of each transaction, including batch numbers, manufacturing dates and supplier certifications. The department believes that this level of documentation will enable quicker recalls if safety issues arise and will give regulators a clearer picture of market dynamics. Industry representatives have expressed worries about potential supply disruptions and increased costs, but the department maintains that patient safety outweighs short‑term commercial challenges.

For Indian readers, especially those living in Kerala, the policy matters because it directly affects the availability and safety of medicines they rely on daily. A more transparent procurement system can reduce the incidence of fake drugs, protect vulnerable patients and restore confidence in the public health system. The next steps will involve monitoring the impact of the restriction on drug prices and supply continuity, as well as assessing whether the temporary measure will be extended or made permanent based on its effectiveness.